Literature DB >> 33158808

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology.

Rossana Bussani1, Edoardo Schneider2, Lorena Zentilin2, Chiara Collesi3, Hashim Ali4, Luca Braga5, Maria Concetta Volpe2, Andrea Colliva2, Fabrizio Zanconati1, Giorgio Berlot1, Furio Silvestri1, Serena Zacchigna6, Mauro Giacca7.   

Abstract

BACKGROUND: COVID-19 is a deadly pulmonary disease with peculiar characteristics, which include variable clinical course and thrombophilia. A thorough understanding of the pathological correlates of the disease is still missing.
METHODS: Here we report the systematic analysis of 41 consecutive post-mortem samples from individuals who died of COVID-19. Histological analysis is complemented by immunohistochemistry for cellular and viral antigens and the detection of viral genomes by in situ RNA hybridization.
FINDINGS: COVID-19 is characterized by extensive alveolar damage (41/41 of patients) and thrombosis of the lung micro- and macro-vasculature (29/41, 71%). Thrombi were in different stages of organization, consistent with their local origin. Pneumocytes and endothelial cells contained viral RNA even at the later stages of the disease. An additional feature was the common presence of a large number of dysmorphic pneumocytes, often forming syncytial elements (36/41, 87%). Despite occasional detection of virus-positive cells, no overt signs of viral infection were detected in other organs, which showed non-specific alterations.
INTERPRETATION: COVID-19 is a unique disease characterized by extensive lung thrombosis, long-term persistence of viral RNA in pneumocytes and endothelial cells, along with the presence of infected cell syncytia. Several of COVID-19 features might be consequent to the persistence of virus-infected cells for the duration of the disease. FUNDING: This work was supported by a King's Together Rapid COVID-19 Call grant from King's College London. MG is supported by the European Research Council (ERC) Advanced Grant 787971 "CuRE" and by Programme Grant RG/19/11/34633 from the British Heart Foundation.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; Endothelial dysfunction; Post-mortem analysis; SARS-CoV-2; Spike protein; Syncytia

Mesh:

Substances:

Year:  2020        PMID: 33158808      PMCID: PMC7677597          DOI: 10.1016/j.ebiom.2020.103104

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   11.205


  57 in total

Review 1.  Diffuse alveolar damage--the role of oxygen, shock, and related factors. A review.

Authors:  A L Katzenstein; C M Bloor; A A Leibow
Journal:  Am J Pathol       Date:  1976-10       Impact factor: 4.307

2.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.

Authors:  Maximilian Ackermann; Stijn E Verleden; Mark Kuehnel; Axel Haverich; Tobias Welte; Florian Laenger; Arno Vanstapel; Christopher Werlein; Helge Stark; Alexandar Tzankov; William W Li; Vincent W Li; Steven J Mentzer; Danny Jonigk
Journal:  N Engl J Med       Date:  2020-05-21       Impact factor: 91.245

3.  Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.

Authors:  Bernadette Schurink; Eva Roos; Teodora Radonic; Ellis Barbe; Catherine S C Bouman; Hans H de Boer; Godelieve J de Bree; Esther B Bulle; Eleonora M Aronica; Sandrine Florquin; Judith Fronczek; Leo M A Heunks; Menno D de Jong; Lihui Guo; Romy du Long; Rene Lutter; Pam C G Molenaar; E Andra Neefjes-Borst; Hans W M Niessen; Carel J M van Noesel; Joris J T H Roelofs; Eric J Snijder; Eline C Soer; Joanne Verheij; Alexander P J Vlaar; Wim Vos; Nicole N van der Wel; Allard C van der Wal; Paul van der Valk; Marianna Bugiani
Journal:  Lancet Microbe       Date:  2020-09-25

4.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Authors:  Ning Tang; Huan Bai; Xing Chen; Jiale Gong; Dengju Li; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

5.  Viral and host factors related to the clinical outcome of COVID-19.

Authors:  Xiaonan Zhang; Yun Tan; Yun Ling; Gang Lu; Feng Liu; Zhigang Yi; Xiaofang Jia; Min Wu; Bisheng Shi; Shuibao Xu; Jun Chen; Wei Wang; Bing Chen; Lu Jiang; Shuting Yu; Jing Lu; Jinzeng Wang; Mingzhu Xu; Zhenghong Yuan; Qin Zhang; Xinxin Zhang; Guoping Zhao; Shengyue Wang; Saijuan Chen; Hongzhou Lu
Journal:  Nature       Date:  2020-05-20       Impact factor: 69.504

6.  Endothelial cell infection and endotheliitis in COVID-19.

Authors:  Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch
Journal:  Lancet       Date:  2020-04-21       Impact factor: 79.321

7.  MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs.

Authors:  Khatia Gabisonia; Giulia Prosdocimo; Giovanni Donato Aquaro; Lucia Carlucci; Lorena Zentilin; Ilaria Secco; Hashim Ali; Luca Braga; Nikoloz Gorgodze; Fabio Bernini; Silvia Burchielli; Chiara Collesi; Lorenzo Zandonà; Gianfranco Sinagra; Marcello Piacenti; Serena Zacchigna; Rossana Bussani; Fabio A Recchia; Mauro Giacca
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

Review 8.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; David Jimenez; Taylor Chuich; Isaac Dreyfus; Elissa Driggin; Caroline Der Nigoghossian; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Joseph A Caprini; Alfonso J Tafur; John R Burton; Dominic P Francese; Elizabeth Y Wang; Anna Falanga; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; P Gabriel Steg; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2020-04-17       Impact factor: 24.094

Review 9.  Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.

Authors:  Mahmoud Gheblawi; Kaiming Wang; Anissa Viveiros; Quynh Nguyen; Jiu-Chang Zhong; Anthony J Turner; Mohan K Raizada; Maria B Grant; Gavin Y Oudit
Journal:  Circ Res       Date:  2020-04-08       Impact factor: 17.367

10.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

View more
  109 in total

Review 1.  COVID-19-Associated Acute Respiratory Distress Syndrome: Lessons from Tissues and Cells.

Authors:  Elizabeth A Middleton; Guy A Zimmerman
Journal:  Crit Care Clin       Date:  2021-05-26       Impact factor: 3.598

2.  Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.

Authors:  Angela Serra; Michele Fratello; Antonio Federico; Ravi Ojha; Riccardo Provenzani; Ervin Tasnadi; Luca Cattelani; Giusy Del Giudice; Pia A S Kinaret; Laura A Saarimäki; Alisa Pavel; Suvi Kuivanen; Vincenzo Cerullo; Olli Vapalahti; Peter Horvath; Antonio Di Lieto; Jari Yli-Kauhaluoma; Giuseppe Balistreri; Dario Greco
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

3.  SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care.

Authors:  Clemens Gutmann; Kaloyan Takov; Sean A Burnap; Bhawana Singh; Hashim Ali; Konstantinos Theofilatos; Ella Reed; Maria Hasman; Adam Nabeebaccus; Matthew Fish; Mark Jw McPhail; Kevin O'Gallagher; Lukas E Schmidt; Christian Cassel; Marieke Rienks; Xiaoke Yin; Georg Auzinger; Salvatore Napoli; Salma F Mujib; Francesca Trovato; Barnaby Sanderson; Blair Merrick; Umar Niazi; Mansoor Saqi; Konstantina Dimitrakopoulou; Rafael Fernández-Leiro; Silke Braun; Romy Kronstein-Wiedemann; Katie J Doores; Jonathan D Edgeworth; Ajay M Shah; Stefan R Bornstein; Torsten Tonn; Adrian C Hayday; Mauro Giacca; Manu Shankar-Hari; Manuel Mayr
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

4.  Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.

Authors:  Luca Braga; Hashim Ali; Ilaria Secco; Elena Chiavacci; Guilherme Neves; Daniel Goldhill; Rebecca Penn; Jose M Jimenez-Guardeño; Ana M Ortega-Prieto; Rossana Bussani; Antonio Cannatà; Giorgia Rizzari; Chiara Collesi; Edoardo Schneider; Daniele Arosio; Ajay M Shah; Wendy S Barclay; Michael H Malim; Juan Burrone; Mauro Giacca
Journal:  Nature       Date:  2021-04-07       Impact factor: 49.962

Review 5.  IL-6 modulation for COVID-19: the right patients at the right time?

Authors:  Paolo Antonio Ascierto; Binqing Fu; Haiming Wei
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 12.469

6.  Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model.

Authors:  Vivek V Thacker; Kunal Sharma; Neeraj Dhar; Gian-Filippo Mancini; Jessica Sordet-Dessimoz; John D McKinney
Journal:  EMBO Rep       Date:  2021-05-27       Impact factor: 8.807

Review 7.  Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19.

Authors:  Aaron Schmid; Marija Petrovic; Kavya Akella; Anisha Pareddy; Sumathilatha Sakthi Velavan
Journal:  Int J Vasc Med       Date:  2021-04-22

8.  Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19.

Authors:  Laurens J Ceulemans; Mona Khan; Seung-Jun Yoo; Bolek Zapiec; Laura Van Gerven; Jan Van Slambrouck; Arno Vanstapel; Dirk Van Raemdonck; Robin Vos; Els Wauters; Joost Wauters; Peter Carmeliet; Peter Mombaerts
Journal:  Lancet Respir Med       Date:  2021-06-09       Impact factor: 30.700

9.  Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.

Authors:  Bo Meng; Steven A Kemp; Guido Papa; Rawlings Datir; Isabella A T M Ferreira; Sara Marelli; William T Harvey; Spyros Lytras; Ahmed Mohamed; Giulia Gallo; Nazia Thakur; Dami A Collier; Petra Mlcochova; Lidia M Duncan; Alessandro M Carabelli; Julia C Kenyon; Andrew M Lever; Anna De Marco; Christian Saliba; Katja Culap; Elisabetta Cameroni; Nicholas J Matheson; Luca Piccoli; Davide Corti; Leo C James; David L Robertson; Dalan Bailey; Ravindra K Gupta
Journal:  Cell Rep       Date:  2021-06-08       Impact factor: 9.995

Review 10.  Invasive mould disease in fatal COVID-19: a systematic review of autopsies.

Authors:  Brittany E Kula; Cornelius J Clancy; M Hong Nguyen; Ilan S Schwartz
Journal:  Lancet Microbe       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.